203 related articles for article (PubMed ID: 26698867)
1. p53 overexpression increases chemosensitivity in multidrug-resistant osteosarcoma cell lines.
Ye S; Shen J; Choy E; Yang C; Mankin H; Hornicek F; Duan Z
Cancer Chemother Pharmacol; 2016 Feb; 77(2):349-56. PubMed ID: 26698867
[TBL] [Abstract][Full Text] [Related]
2. Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance.
Liu T; Li Z; Zhang Q; De Amorim Bernstein K; Lozano-Calderon S; Choy E; Hornicek FJ; Duan Z
Oncotarget; 2016 Dec; 7(50):83502-83513. PubMed ID: 27835872
[TBL] [Abstract][Full Text] [Related]
3. Novel gene P28GANK confers multidrug resistance by modulating the expression of MDR-1, Bcl-2 and Bax in osteosarcoma cells.
Wang G; Rong J; Zhou Z; Duo J
Mol Biol (Mosk); 2010; 44(6):1010-7. PubMed ID: 21287809
[TBL] [Abstract][Full Text] [Related]
4. Restoration of wild-type p53 activity in p53-null HL-60 cells confers multidrug sensitivity.
Ju JF; Banerjee D; Lenz HJ; Danenberg KD; Schmittgen TC; Spears CP; Schönthal AH; Manno DJ; Hochhauser D; Bertino JR; Danenberg PV
Clin Cancer Res; 1998 May; 4(5):1315-22. PubMed ID: 9607592
[TBL] [Abstract][Full Text] [Related]
5. Wild-type p53 gene transfection in human cultured sarcomas: effect of CDDP.
Endo K; Kuratate I; Watanabe M; Yoshida H; Teshima R; Osaki M; Ito H
Oncol Rep; 2001; 8(3):637-42. PubMed ID: 11295094
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the chemosensitivity of head and neck cancer cells based on the diverse function of mutated-p53.
Shinagawa Y; Kawamata H; Omotehara F; Nakashiro K; Hoque MO; Furihata T; Horiuchi H; Imai Y; Fujimori T; Fujibayashi T
Int J Oncol; 2003 Feb; 22(2):383-9. PubMed ID: 12527938
[TBL] [Abstract][Full Text] [Related]
7. p53-dependent apoptosis in melanoma cells after treatment with camptothecin.
Li G; Bush JA; Ho VC
J Invest Dermatol; 2000 Mar; 114(3):514-9. PubMed ID: 10692111
[TBL] [Abstract][Full Text] [Related]
8. Sensitization of multidrug resistant human ostesarcoma cells to Apo2 Ligand/TRAIL-induced apoptosis by inhibition of the Akt/PKB kinase.
Cenni V; Maraldi NM; Ruggeri A; Secchiero P; Del Coco R; De Pol A; Cocco L; Marmiroli S
Int J Oncol; 2004 Dec; 25(6):1599-608. PubMed ID: 15547696
[TBL] [Abstract][Full Text] [Related]
9. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
[TBL] [Abstract][Full Text] [Related]
10. The different regulatory effects of p53 status on multidrug resistance are determined by autophagy in ovarian cancer cells.
Kong D; Ma S; Liang B; Yi H; Zhao Y; Xin R; Cui L; Jia L; Liu X; Liu X
Biomed Pharmacother; 2012 Jun; 66(4):271-8. PubMed ID: 22564245
[TBL] [Abstract][Full Text] [Related]
11. Reversion effects of curcumin on multidrug resistance of MNNG/HOS human osteosarcoma cells in vitro and in vivo through regulation of P-glycoprotein.
Si M; Zhao J; Li X; Tian JG; Li YG; Li JM
Chin Med J (Engl); 2013 Nov; 126(21):4116-23. PubMed ID: 24229684
[TBL] [Abstract][Full Text] [Related]
12. Exogenous mutant p53 DNA enhanced cisplatin-induced apoptosis in TSGH-8301 human bladder cancer cells.
Chang FL; Ling YF; Lai MD
Anticancer Res; 2000; 20(1A):329-36. PubMed ID: 10769676
[TBL] [Abstract][Full Text] [Related]
13. Lack of p53 augments thymoquinone-induced apoptosis and caspase activation in human osteosarcoma cells.
Roepke M; Diestel A; Bajbouj K; Walluscheck D; Schonfeld P; Roessner A; Schneider-Stock R; Gali-Muhtasib H
Cancer Biol Ther; 2007 Feb; 6(2):160-9. PubMed ID: 17218778
[TBL] [Abstract][Full Text] [Related]
14. Differentially expressed genes in multidrug resistant variants of U-2 OS human osteosarcoma cells.
Chano T; Mori K; Scotlandi K; Benini S; Lapucci C; Manara MC; Serra M; Picci P; Okabe H; Baldini N
Oncol Rep; 2004 Jun; 11(6):1257-63. PubMed ID: 15138564
[TBL] [Abstract][Full Text] [Related]
15. Multidrug resistance and malignancy in human osteosarcoma.
Scotlandi K; Serra M; Nicoletti G; Vaccari M; Manara MC; Nini G; Landuzzi L; Colacci A; Bacci G; Bertoni F; Picci P; Campanacci M; Baldini N
Cancer Res; 1996 May; 56(10):2434-9. PubMed ID: 8625324
[TBL] [Abstract][Full Text] [Related]
16. RAIDD expression is impaired in multidrug resistant osteosarcoma cell lines.
Yang C; Hornicek FJ; Wood KB; Schwab JH; Mankin H; Duan Z
Cancer Chemother Pharmacol; 2009 Aug; 64(3):607-14. PubMed ID: 19125251
[TBL] [Abstract][Full Text] [Related]
17. Possible involvement of bcl-2 suppression in wild-type p53 gene-dependent cell growth repression in rat osteosarcoma cells.
Honoki K; Tsujiuchi T; Tsutsumi M; Kido A; Morishita T; Yoshimoto M; Miyauchi Y; Mii Y; Tamai S; Konishi Y
Toxicol Pathol; 2000; 28(4):575-9. PubMed ID: 10930045
[TBL] [Abstract][Full Text] [Related]
18. Characterization and modulation of drug resistance of human paediatric rhabdomyosarcoma cell lines.
Cocker HA; Pinkerton CR; Kelland LR
Br J Cancer; 2000 Aug; 83(3):338-45. PubMed ID: 10917549
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of bax in human glioma cell lines.
Vogelbaum MA; Tong JX; Perugu R; Gutmann DH; Rich KM
J Neurosurg; 1999 Sep; 91(3):483-9. PubMed ID: 10470825
[TBL] [Abstract][Full Text] [Related]
20. Adenovirus-mediated overexpression of p14(ARF) induces p53 and Bax-independent apoptosis.
Hemmati PG; Gillissen B; von Haefen C; Wendt J; Stärck L; Güner D; Dörken B; Daniel PT
Oncogene; 2002 May; 21(20):3149-61. PubMed ID: 12082630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]